Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, and Cancer Treatment and Pharmacology.
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
23P Clinical, pathological and gene expression features of HER2-low breast cancer
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers